We’re in the infancy of the genomic revolution. Today, more than 70,000 genetic tests exist, many with the potential to make life-changing improvements in health. However, even with all these scientific breakthroughs, we understand the functionality of less than two percent of our genome – with decades of new discoveries to unravel. That leaves payers …
We have all been affected by cancer, whether it be a new diagnosis in a friend, relative, coworker, pet, or even a personal diagnosis. Breast cancer is especially common in this country, with one in eight women developing breast cancer by age 70. Researchers have identified multiple genes that can increase the risk for breast …
Not long ago, we realized we needed a comprehensive tool that provided a prescriptive set of controls, which we could use to maintain compliance across a range of regulatory requirements. We pursued, then in May of this year, InformedDNA was awarded the HITRUST CSF Certification for our Utilization Management and Data Analysis systems. The Certified …
InformedDNA will be exhibiting and presenting at Mayo Clinic’s Individualizing Medicine Conference, September 12-13, in Rochester, MN. About the conference: Attendees will discover practical applications of genomic medicine, integrating precision medicine therapies into patient care. Designed with the professional in mind, concurrent sessions offer will offer practical genomic medicine applications in practice to in-depth discussions …
Visit Us at Mayo Clinic’s Individualizing Medicine Conference Read More »
Visit InformedDNA’s booth at the American College of Surgeons Cancer Programs Annual Conference, September 5-7 in Chicago, IL. About the conference: The American College of Surgeons (ACS) Annual Cancer Programs Conference provides attendees with cutting-edge ways to deliver high-quality, patient-centered, multidisciplinary care to patients with cancer. Developed with input from volunteers and staff from the …
Join Us at the American College of Surgeons Cancer Programs Annual Conference Read More »
More than 70% of new gene therapies in development target rare diseases, half of which affect children. But as the growth of genetic therapies designed to treat these rare conditions continues to climb, the need for expert guidance around who should receive these therapies has intensified. Decisions around genetic-driven therapies leave little margin for error. …
